NCT04838808

Rivaroxaban in Type 2 Myocardial Infarctions

Rivaroxaban in Type 2 Myocardial Infarctions: A Feasibility, Placebo-controlled, Double-blinded, Randomized Controlled Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: University of Alberta · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.

Detailed description

This trial is an investigator-initiated prospective, single-center, placebo-controlled, double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice daily) for 90-days following a type 2 myocardial infarction. The primary feasibility outcome is time to recruitment of 100 participants, stratified by sex.

Conditions

• Type II Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Rivaroxaban 2.5 MG [Xarelto]	Rivaroxaban 2.5mg twice daily for 90-days
DRUG	Placebo	Placebo tablet twice daily for 90-days

Timeline

• Start date: 2021-04-05
• Primary completion: 2022-05-12
• Completion: 2023-01-03
• First posted: 2021-04-09
• Last updated: 2023-03-27

Locations

1 site across 1 country: Canada